BioSpace News Archive

Independent test-institutes have confirmed that Prebona Disinfect is extremely effective against the coronavirus - SARS CoV-2, COVID-19.

The Board of Directors of Moberg Pharma AB has resolved to carry out a fully guaranteed issue of new ordinary shares and warrants with preferential rights for existing shareholders of approximately SEK 150 million before transaction costs.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced that industry veteran Susan Benton was appointed to its board of directors, effective November 5, 2020.

Q3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06) ‒ ‒ Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16‒ ‒ Updating 2020 Full Year Financial Outlook ‒

- Third quarter net sales of $1.929 billion increased 2.0%, and increased 1.1% on a constant currency basis - Third quarter diluted earnings per share were $1.16; adjusted diluted earnings per share were $1.81

-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT biomarker selection trial of vopratelimab in combination with JTX-4014- -Company to host conference call and webcast today at 8:00 AM ET-

Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET

Studies confirm improvement achieved and maintained through one year of active treatment with similar scores for patients switching from placebo to TREMFYA TREMFYA is the first and only U.S. FDA-approved selective anti-IL-23 therapy for active psoriatic arthritis and the only therapy for psoriatic arthritis to have improvement in fatigue as measured by FACIT-F in the product label

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 52,250 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Third quarter 2020 revenue of $129 million Third quarter 2020 net loss of $42 million Third quarter 2020 Adjusted EBITDA 1 of $53 million Generated cash flow from operations of $113 million in the first nine months of 2020 Concluded the quarter with a cash and cash equivalents balance of $141 million